Cargando…

Neutrophilic noncoding RNAs predict outcomes of acute ischemic stroke patients treated with recombinant tissue plasminogen activator

There’s no evidence demonstrating the association between noncoding RNAs levels before IV recombinant tissue plasminogen activator (rtPA) administration and the outcomes of acute ischemic stroke (AIS). 145 AIS patients received rtPA treatment were recruited at the stroke center from 2018 to 2019, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ziping, Li, Lingzhi, Tao, Zhen, Wang, Rongliang, Zhao, Haiping, Zheng, Yangmin, Yang, Zhenhong, Zhong, Liyuan, Fan, Junfen, Luo, Yumin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582270/
https://www.ncbi.nlm.nih.gov/pubmed/36278201
http://dx.doi.org/10.3389/fphar.2022.1003806
_version_ 1784812794426687488
author Han, Ziping
Li, Lingzhi
Tao, Zhen
Wang, Rongliang
Zhao, Haiping
Zheng, Yangmin
Yang, Zhenhong
Zhong, Liyuan
Fan, Junfen
Luo, Yumin
author_facet Han, Ziping
Li, Lingzhi
Tao, Zhen
Wang, Rongliang
Zhao, Haiping
Zheng, Yangmin
Yang, Zhenhong
Zhong, Liyuan
Fan, Junfen
Luo, Yumin
author_sort Han, Ziping
collection PubMed
description There’s no evidence demonstrating the association between noncoding RNAs levels before IV recombinant tissue plasminogen activator (rtPA) administration and the outcomes of acute ischemic stroke (AIS). 145 AIS patients received rtPA treatment were recruited at the stroke center from 2018 to 2019, and 103 patients were included in this study. A panel of noncoding RNAs (miRNA-23a, miRNA-193a, miRNA-128, miRNA-99a, miRNA-let-7a, miRNA-494, miRNA-424, and lncRNA H19) were measured in the circulating neutrophils of AIS patients before rtPA treatment. Endpoints included excellent outcome (modified Rankin Scale score [mRS] 0–1) or poor outcome (mRS > 1) at 3 months and symptomatic intracerebral hemorrhage (sICH) after rtPA treatment. Among the eight noncoding RNAs detected in circulating neutrophils of the 103 participants, miRNA-23a levels were associated with the stroke severity on admission and symptom progression at 24 h after rtPA treatment. A noncoding RNA score composed of miRNA-23a, miRNA-99a, and lncRNA H19 was screened to predict the functional outcome at 3 months and the incidence of sICH after rtPA treatment. In the logistic regression analysis, the noncoding RNA score ≥ −0.336 (OR = 2.862 [1.029–7.958], p = 0.044) was an independent predictor of the poor outcome at 3 months after adjustment of clinical variables, the addition of the noncoding RNA score to the clinical model improved the discrimination (IDI% = 4.68 [0.65–8.71], p = 0.020), as well as the net reclassification (NRI% = 33.04 [0.54–71.49], p = 0.016). The noncoding RNA score ≥ −0.336 (OR = 5.250 [1.096–25.135], p = 0.038) was also independently predicted the sICH, the addition of the noncoding RNA score to the clinical variables improved discrimination and reclassification as well. The noncoding RNA score was also associated with the infarct volume and symptom improvement at 7 days after rtPA treatment. In conclusion, a higher neutrophilic noncoding RNA score provides predictive value to identify AIS patients with worse outcomes after rtPA treatment. miRNA-23a, miRNA-99a, and lncRNA H19 are worth further investigation for their effects in thrombolysis after AIS.
format Online
Article
Text
id pubmed-9582270
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95822702022-10-21 Neutrophilic noncoding RNAs predict outcomes of acute ischemic stroke patients treated with recombinant tissue plasminogen activator Han, Ziping Li, Lingzhi Tao, Zhen Wang, Rongliang Zhao, Haiping Zheng, Yangmin Yang, Zhenhong Zhong, Liyuan Fan, Junfen Luo, Yumin Front Pharmacol Pharmacology There’s no evidence demonstrating the association between noncoding RNAs levels before IV recombinant tissue plasminogen activator (rtPA) administration and the outcomes of acute ischemic stroke (AIS). 145 AIS patients received rtPA treatment were recruited at the stroke center from 2018 to 2019, and 103 patients were included in this study. A panel of noncoding RNAs (miRNA-23a, miRNA-193a, miRNA-128, miRNA-99a, miRNA-let-7a, miRNA-494, miRNA-424, and lncRNA H19) were measured in the circulating neutrophils of AIS patients before rtPA treatment. Endpoints included excellent outcome (modified Rankin Scale score [mRS] 0–1) or poor outcome (mRS > 1) at 3 months and symptomatic intracerebral hemorrhage (sICH) after rtPA treatment. Among the eight noncoding RNAs detected in circulating neutrophils of the 103 participants, miRNA-23a levels were associated with the stroke severity on admission and symptom progression at 24 h after rtPA treatment. A noncoding RNA score composed of miRNA-23a, miRNA-99a, and lncRNA H19 was screened to predict the functional outcome at 3 months and the incidence of sICH after rtPA treatment. In the logistic regression analysis, the noncoding RNA score ≥ −0.336 (OR = 2.862 [1.029–7.958], p = 0.044) was an independent predictor of the poor outcome at 3 months after adjustment of clinical variables, the addition of the noncoding RNA score to the clinical model improved the discrimination (IDI% = 4.68 [0.65–8.71], p = 0.020), as well as the net reclassification (NRI% = 33.04 [0.54–71.49], p = 0.016). The noncoding RNA score ≥ −0.336 (OR = 5.250 [1.096–25.135], p = 0.038) was also independently predicted the sICH, the addition of the noncoding RNA score to the clinical variables improved discrimination and reclassification as well. The noncoding RNA score was also associated with the infarct volume and symptom improvement at 7 days after rtPA treatment. In conclusion, a higher neutrophilic noncoding RNA score provides predictive value to identify AIS patients with worse outcomes after rtPA treatment. miRNA-23a, miRNA-99a, and lncRNA H19 are worth further investigation for their effects in thrombolysis after AIS. Frontiers Media S.A. 2022-10-06 /pmc/articles/PMC9582270/ /pubmed/36278201 http://dx.doi.org/10.3389/fphar.2022.1003806 Text en Copyright © 2022 Han, Li, Tao, Wang, Zhao, Zheng, Yang, Zhong, Fan and Luo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Han, Ziping
Li, Lingzhi
Tao, Zhen
Wang, Rongliang
Zhao, Haiping
Zheng, Yangmin
Yang, Zhenhong
Zhong, Liyuan
Fan, Junfen
Luo, Yumin
Neutrophilic noncoding RNAs predict outcomes of acute ischemic stroke patients treated with recombinant tissue plasminogen activator
title Neutrophilic noncoding RNAs predict outcomes of acute ischemic stroke patients treated with recombinant tissue plasminogen activator
title_full Neutrophilic noncoding RNAs predict outcomes of acute ischemic stroke patients treated with recombinant tissue plasminogen activator
title_fullStr Neutrophilic noncoding RNAs predict outcomes of acute ischemic stroke patients treated with recombinant tissue plasminogen activator
title_full_unstemmed Neutrophilic noncoding RNAs predict outcomes of acute ischemic stroke patients treated with recombinant tissue plasminogen activator
title_short Neutrophilic noncoding RNAs predict outcomes of acute ischemic stroke patients treated with recombinant tissue plasminogen activator
title_sort neutrophilic noncoding rnas predict outcomes of acute ischemic stroke patients treated with recombinant tissue plasminogen activator
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582270/
https://www.ncbi.nlm.nih.gov/pubmed/36278201
http://dx.doi.org/10.3389/fphar.2022.1003806
work_keys_str_mv AT hanziping neutrophilicnoncodingrnaspredictoutcomesofacuteischemicstrokepatientstreatedwithrecombinanttissueplasminogenactivator
AT lilingzhi neutrophilicnoncodingrnaspredictoutcomesofacuteischemicstrokepatientstreatedwithrecombinanttissueplasminogenactivator
AT taozhen neutrophilicnoncodingrnaspredictoutcomesofacuteischemicstrokepatientstreatedwithrecombinanttissueplasminogenactivator
AT wangrongliang neutrophilicnoncodingrnaspredictoutcomesofacuteischemicstrokepatientstreatedwithrecombinanttissueplasminogenactivator
AT zhaohaiping neutrophilicnoncodingrnaspredictoutcomesofacuteischemicstrokepatientstreatedwithrecombinanttissueplasminogenactivator
AT zhengyangmin neutrophilicnoncodingrnaspredictoutcomesofacuteischemicstrokepatientstreatedwithrecombinanttissueplasminogenactivator
AT yangzhenhong neutrophilicnoncodingrnaspredictoutcomesofacuteischemicstrokepatientstreatedwithrecombinanttissueplasminogenactivator
AT zhongliyuan neutrophilicnoncodingrnaspredictoutcomesofacuteischemicstrokepatientstreatedwithrecombinanttissueplasminogenactivator
AT fanjunfen neutrophilicnoncodingrnaspredictoutcomesofacuteischemicstrokepatientstreatedwithrecombinanttissueplasminogenactivator
AT luoyumin neutrophilicnoncodingrnaspredictoutcomesofacuteischemicstrokepatientstreatedwithrecombinanttissueplasminogenactivator